Floatz logo

ly2584702

Neuroendocrine Tumors

Eli Lilly and CompanyPhase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
73/ 100

Competitive context

62 Active assets in the Neuroendocrine Tumors cohort.

Asset / SponsorPhaseRating
Eloxatin
ITM Solucin GmbH
Phase 3BB
FLUOROURACILUM
ITM Solucin GmbH
Phase 3BB
Bms-907351
Fox Chase Cancer Center
Phase 3BB
Irinotecan
First Affiliated Hospital Xi'an Jiaotong University
Phase 4BB
Pasireotide
RECORDATI GROUP
Phase 4BB

View all 50 →

Same molecule, other indications

ly2584702 is also rated in:

metastatic neoplasmDormant
CC
Indicative ·
43 / 100
View asset →
non-small cell lung carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
cancerDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →